[{"id":"3d13cf21-beef-41a2-b3d5-e4a215e42b93","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731752","created_at":"2023-02-16T15:00:42.453Z","updated_at":"2024-07-02T16:35:55.402Z","phase":"Phase 1","brief_title":"Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05731752","lead_sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HX-009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/04/2020","start_date":" 06/04/2020","primary_txt":" Primary completion: 11/04/2023","primary_completion_date":" 11/04/2023","study_txt":" Completion: 10/28/2024","study_completion_date":" 10/28/2024","last_update_posted":"2023-02-16"},{"id":"d97d5602-5b0a-4373-a674-c90d9460945c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04886271","created_at":"2022-04-28T20:53:50.027Z","updated_at":"2024-07-02T16:36:11.269Z","phase":"Phase 2","brief_title":"Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT04886271","lead_sponsor":"Waterstone Hanxbio Pty Ltd","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HX-009"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/12/2021","start_date":" 05/12/2021","primary_txt":" Primary completion: 12/10/2022","primary_completion_date":" 12/10/2022","study_txt":" Completion: 02/10/2023","study_completion_date":" 02/10/2023","last_update_posted":"2022-04-28"}]